Clinical Trials Directory

Trials / Completed

CompletedNCT02812550

Full-spectrum Endoscopy in Colorectal Cancer Screening

Impact of Full-spectrum Endoscopy in Colorectal Cancer Screening: Randomized Controlled Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
249 (actual)
Sponsor
Hospital del Rio Hortega · Academic / Other
Sex
All
Age
50 Years – 69 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare the adenoma detection rates of full-spectrum endoscopy versus standard forward-viewing colonoscopy in colorectal cancer screening programme.

Detailed description

Colorectal cancer is the third most common neoplasia and the second leading cause of cancer death in West countries. Colonoscopy is the gold standard for prevention of colorectal cancer disease. Screening for colorectal cancer with biennial faecal occult blood testing is a widely used strategy followed by colonoscopy for those with a positive test. Colonoscopy identifies polyps during the procedure as well as polyp removal in order to prevent progression to cancer. Although, interval cancer appears after a colonoscopy because of 22-28% of polyp missed rates. Advanced Technology may improve adenoma detection rates so decrease interval cancer and reduce mortally. Full-spectrum endoscopy with 330º angle vision decrease adenoma miss rate in general population. The investigators conducted a randomized trial in patients from colorectal cancer screening programme (aged 50-69 years) after faecal immunological test positive. One arm the colonoscopy is performed with standard forward view colonoscopy (170º angle view) and the other arm is performed with full-spectrum endoscopy (EndoChoice) (330º angle view)

Conditions

Interventions

TypeNameDescription
PROCEDUREcolonoscopy procedureendoscopy performed with a standard forward view colonoscopy or with full-spectrum endoscopy

Timeline

Start date
2015-05-01
Primary completion
2016-05-01
Completion
2016-06-01
First posted
2016-06-24
Last updated
2016-06-24

Source: ClinicalTrials.gov record NCT02812550. Inclusion in this directory is not an endorsement.